Advertisement

Topics

Grünenthal Company Profile

21:25 EDT 26th April 2017 | BioPortfolio

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti Grünenthal sono commercializzati in oltre 80 Paesi e il numero delle filiali è in continua crescita. Grünenthal occupa circa 4.800 persone a livello mondiale, persone che hanno dato un grande contributo per il successo della Società.L'ulteriore consolidamento attraverso una ricerca innovativa è una parte integrante della politica della nostra Società. L'ambizione di Grünenthal è quella di essere una società leader nella Ricerca e Sviluppo in campi selezionati: l'area dolore è la nostra competenza core.

Location

Via Correggio, 43
Milano
20149
Italy

Contact

Phone: 39-02-43051
Fax: 39-02-430555
Email: dg@grunenthal.com


News Articles [28 Associated News Articles listed on BioPortfolio]

View From The Top: Growing Grünenthal

As he leaves after 23 years at the firm, outgoing CEO Eric-Paul Pâques talks about Grünenthal's growth and strategic priorities...    

Grünenthal to acquire rights to PN pain drug

Family-owned German drugmaker Grünenthal has negotiated a deal to acquire rights to market a dermal…

Grünenthal New CEO: My Strategic Priorities

Gabriel Baertschi, the new head of midsize German pharma firm Grünenthal talks to Jo Shorthouse about his first moves as...    

Grünenthal Group acquires Adhesys Medical

The Grünenthal Group has acquired Adhesys Medical and its US-based affiliate Adhesys Medical, a medical device Startup company focused on the development of adhesives used in surgery.

Grünenthal Acquires Adhesys Medical To Expand Medical Device Pipeline

German pharma company Grünenthal is expanding its medical device portfolio with the acquisition of surgical adhesives specialist Adhesys Medical. The...  

Grünenthal to buy rights to PNP drug from Astellas Pharma Europe

Grünenthal has agreed to acquire commercialization rights of Qutenza in Europe from Astellas Pharma Europe.

Astellas Announces Transfer of Qutenza to Grünenthal

TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas ...

Grünenthal signs agreement with Astellas for dermal patch Qutenza rights

German-based Grünenthal Group has signed an agreement with Astellas Pharma Europe for the exclusive rights to the dermal patch Qutenza (capsaicin 8%) in Europe, the Middle East and Africa.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

Grünenthal Group

The Grünenthal Group is an independent, family-owned company, headquartered in Aachen, Germany. It is present in 32 countries with affiliates in Europe, Latin America and the U...

Grünenthal

Grünenthal è una società farmaceutica indipendente, basata sulla ricerca con operazioni internazionali. E' sempre stata una società a capitale privato fin dalla sua fondazione nel 1946. I prodotti...

Gr?nenthal

Grünenthal GmbH

Nil

More Information about "Grünenthal" on BioPortfolio

We have published hundreds of Grünenthal news stories on BioPortfolio along with dozens of Grünenthal Clinical Trials and PubMed Articles about Grünenthal for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Grünenthal Companies in our database. You can also find out about relevant Grünenthal Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record